非小细胞肺癌三级淋巴结构评估及临床应用中国专家共识(2025版)  

Chinese Expert Consensus on Assessment and Clinical Application of Tertiary Lymphoid Structure for Non-small Cell Lung Cancer(2025 Version)

作　　者：中国抗癌协会肿瘤病理专业委员会肺癌协作组 中国临床肿瘤学会非小细胞肺癌专业委员会 林冬梅 周彩存 李媛 沈波[8] Lung Cancer Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association;Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology;Dongmei LIN;Caicun ZHOU;Yuan LI;Bo SHEN

机构地区：[1]不详 [2]北京大学肿瘤医院 [3]暨北京市肿瘤防治研究所病理科 [4]恶性肿瘤发病机制及转化研究教育部重点实验室 [5]上海市东方医院肿瘤科 [6]复旦大学附属肿瘤医院病理科 [7]复旦大学上海医学院肿瘤学系 [8]江苏省肿瘤医院/南京医科大学附属肿瘤医院内科

出　　处：《中国肺癌杂志》2025年第2期95-104,共10页Chinese Journal of Lung Cancer

摘　　要：三级淋巴结构(tertiary lymphoid structure,TLS)在肿瘤微环境中发挥着至关重要的作用,影响肿瘤的发生发展。作为预测肿瘤患者预后及治疗反应的一种新兴生物标志物,TLS越来越受到重视。但目前对于TLS的评估缺乏统一的标准,且TLS在不同肿瘤组织中存在差异,为该标志物在临床转化中的应用带来困扰。为满足非小细胞肺癌(non-small cell lung cancer,NSCLC)临床诊治需求,本共识围绕NSCLC TLS的定义、临床意义、检测内容及评估方法等基本要点,结合相关研究和中国临床实践,为临床TLS评估及应用提供标准化和规范化建议,以提高临床医师及病理检测诊断人员对TLS的认识,为NSCLC TLS检测临床应用提供参考依据。The tertiary lymphoid structure(TLS)plays a crucial role in the tumor microenvironment,influenc-ing tumor development and progression.As an emerging biomarker for predicting the prognosis and treatment response in cancer patients,TLS has received increasing attention.However,there is currently a lack of standardized evaluation criteria for TLS,and significant differences exist in TLS across different tumor tissues.This poses challenges for the clinical application of this biomarker in translation.To meet the clinical diagnosis and treatment needs of non-small cell lung cancer(NSCLC),this consensus focuses on the definition,clinical significance,testing components,and assessment methods of TLS in NSCLC.Combining relevant research and Chinese clinical practice,it provides standardized and normalized suggestions for the clinical assessment and application of TLS,so as to improve the understanding of TLS among clinicians and pathologists,and provide a reference basis for the clinical application of the detection of TLS in NSCLC.

关 键 词：肺肿瘤 三级淋巴结构 评估 临床应用 共识 

分 类 号：R73[医药卫生—肿瘤]